FDA Grants Full Approval to Sacituzumab Govitecan-Based Regimens for First-Line TNBC, as Trial Data Show Benefit Extending Past Initial Progression

Media coverage

• Title	FDA Grants Full Approval to Sacituzumab Govitecan-Based Regimens for First-Line TNBC, as Trial Data Show Benefit Extending Past Initial Progression
  Media name/outlet	Onco'Zine
  Country/Territory	United States
  Date	3/09/26
  URL	ct.moreover.com/?a=60337751430&p=1gw&v=1&x=f4yx4ruFR-RYrBHFLgrlAQ
  Persons	Yumin Zhang